Biovail’s Ralivia receives approvable letter
Biovail has received an approvable letter from the FDA for the drug, but it has yet to be approved.
There's a reason pharma lags on the programmatic adoption curve: It's a heavily regulated industry, and there are concerns around privacy.
Where are the discussions about applying proven behavior change models or the principles of adult learning and health literacy?
Such intense interest in health content is a rich opportunity to engage, inform, support, and motivate key customer constituencies.